CLAUDIN 18.2 CELLULAR THERAPY & GASTRIC CARE

Advanced Stomach Cancer Care in China

Stomach (gastric) cancer is widely treated in East Asia, giving Chinese surgeons and oncologists unmatched clinical mastery. China holds world-first approvals for Claudin 18.2 targeted cellular therapies and dual-target immunotherapies, offering groundbreaking solutions for advanced and metastatic gastric cancer alongside organ-preserving surgical techniques.

TARGETED BIOLOGICS & GASTRIC SURGERY

Key Stomach Cancer Treatments in China

Breakthrough Claudin 18.2 living cell therapy, robotic gastrectomy, and heated intraperitoneal chemotherapy (HIPEC).

Claudin 18.2 CAR-T Cell Therapy

China's groundbreaking living cell therapy and targeted antibodies specifically designed to destroy Claudin 18.2 expressing gastric tumor cells.

Robotic & Keyhole Gastrectomy

Minimally invasive keyhole surgery that removes the tumor with complete lymph node clearance while preserving healthy digestive passages.

Heated Chemotherapy (HIPEC)

Circulating heated chemotherapy inside the abdomen during surgery to eliminate microscopic tumor cells and prevent peritoneal recurrence.

WHY CHOOSE US

Why Choose China Cancer Help for Stomach Cancer Care

A specialized clinical pathway connecting international patients with China’s top gastric oncology institutes.

China accounts for a significant portion of global gastric cancer treatments, driving world-leading research and clinical trials. Chinese medical institutions achieved the world’s first regulatory approvals for Claudin 18.2 directed therapies and have pioneered effective neoadjuvant conversion protocols that make previously inoperable gastric tumors surgically removable.

Before traveling, your endoscopy records, CT scans, and biomarker testing (Claudin 18.2, HER2, PD-L1) are reviewed by senior gastric oncologists. Treatment is delivered in certified tertiary university hospitals with full bilingual bedside assistance and itemized public billing.

CASE EVALUATION PATHWAY

A Structured Pathway from Records to Care

A transparent, four-stage continuum connecting preliminary clinical evaluation to official hospital acceptance, specialized inpatient care, and ongoing continuity.

01. Submit Records Online

Upload pathology reports, biomarker NGS profiles, and imaging scans through our confidential clinical intake portal.

02. Remote MDT Review

National Clinical Research Center oncology boards evaluate eligibility, target expression, and formulate a customized protocol.

03. Visa & Admission

Receive official hospital medical invitation letters, transparent pricing schedules, and expedited department admission.

04. Treatment & Follow-up

Inpatient cellular or particle therapy in ISO-GMP cleanrooms with dedicated bilingual escorts and remote post-discharge care.

PATIENT FAQS

Frequently Asked Questions

Key clinical, financial, and logistical insights for international Stomach Cancer patients considering advanced treatment in China.

Claudin 18.2 is a protein present in up to 70% of gastric cancer cells. China’s approved CAR-T and targeted antibody therapies zero in on this protein, offering remarkable tumor shrinkage in advanced cases.
Yes. Modern conversion therapy combining targeted pills, immunotherapy, and chemotherapy often shrinks the tumor dramatically, allowing curative surgical resection.
Hyperthermic Intraperitoneal Chemotherapy delivers heated cancer drugs directly into the abdominal cavity during surgery, effectively treating or preventing peritoneal metastasis.
Dedicated clinical dietitians and nurses provide customized post-operative dietary guidance and enzyme replacement plans to ensure smooth recovery and weight maintenance.

GASTRIC ONCOLOGY CLINICAL ASSESSMENT

Request a Confidential Case Review for Stomach Cancer

Submit your endoscopy reports, CT/MRI scans, biopsy results, and treatment history for a comprehensive review by our specialist digestive oncology team.

    Stomach Cancer